GI360 Publications

2024

• Fecal bacteria and short-chain fatty acids in irritable bowel syndrome: Relations to subtype
• Factors underlying the long-term efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome
• Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
  
• A Systematic Review: Fecal Bacterial Profile in Patients with Irritable Bowel Syndrome Analyzed with the GA-Map Dysbiosis Test Based on the 16S rRNA Gene of Bacterial Species or Groups
  
• Prolonged Intake of Luvos Healing Earth does not alter the Composition of the Gut Microbiota in Patients with Diarrhea-predominant Irritable Bowel Syndrome and Healthy Controls
  

2023

• Is microbiota characterization a useful tool in clinical practice? An exploratory analysis of patients from the IBS
  
• Exploring the gut microbiota in patients with pre-diabetes and treatment na?ve diabetes type 2
  

2022

• Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome
  
• Replacing saturated fatty acids with polyunsaturated fatty acids increases the abundance of Lachnospiraceae and is associated with reduced total cholesterol levels-a randomized controlled trial in healthy individuals
• Gut microbiota is associated with dietary intake and metabolic markers in healthy individuals
  
• Variability in the Pre-Analytical Stages Influences Microbiome Laboratory Analyses
  
• Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation
  
• Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids
  
• The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms
  
• Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation
  
• Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet
• Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
  
• Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome
  

2021

• Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID)
  
• Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome
  
• A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome
  
• Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome
  
• The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome
• Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis
  
• Determining Gut Microbial Dysbiosis: a Review of Applied Indexes for Assessment of Intestinal Microbiota Imbalances
  

2020

• Effects of high intake of cod or salmon on gut microbiota profile, faecal output and serum concentrations of lipids and bile acids in overweight adults: a randomised clinical trial
  
• Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study
  
• Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
  
• Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome
  
• Changes in serum zonulin in individuals with morbid obesity after weight-loss interventions: a prospective cohort study
• Effects of Dietary Fibres on Acute Indomethacin-Induced Intestinal Hyperpermeability in the Elderly: A Randomised Placebo Controlled Parallel Clinical Trial
  
• Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study
  
• Fecal microbiota composition is linked to the postoperative disease course in patients with Crohn's disease
  
• Changes in Faecal Short-Chain Fatty Acids after Weight-Loss Interventions in Subjects with Morbid Obesity
  
• Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation
  

2019

• Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study
  
• A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin
• Are Nonnutritive Sweeteners Obesogenic? Associations between Diet, Faecal Microbiota, and Short-Chain Fatty Acids in Morbidly Obese Subjects
  
• Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)
  
• Fecal microbiota profiles in treatment-na?ve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome
  

2018

• Separating "good" from "bad" faecal dysbiosis - evidence from two cross-sectional studies
  
• The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation
  
• Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study
  
• Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs
• Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome
  
• Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity
  

2017

• Severe intestinal dysbiosis is prevalent in primary Sj?gren's syndrome and is associated with systemic disease activity
• The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis
  
• Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome
  

2016

• Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease
  
• Bead-beating artefacts in the Bacteroidetes to Firmicutes ratio of the human stool metagenome
  
• Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
  

2015

• Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD
  

2013

• Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients

2011

• Temporal development of the infant gut microbiota in immunoglobulin E-sensitized and nonsensitized children determined by the GA-map infant array